|Articles|April 16, 2020
Accelerated Enrollment Solutions Launches Patient-Transfer Program to Support Trial Continuity During COVID-19 Pandemic
Advertisement
Accelerated Enrollment Solutions (AES) has launched a program to help biopharmaceutical companies maintain business continuity during the global COVID-19 pandemicby transferring clinical trial patients to AES’ dedicated research sites from other research facilities.
To find out more, click
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
NIMBLE Trial Reveals New Insights on Complement Inhibition in gMGSeptember 15th 2025
Q&A: Strategies for Successful Global Clinical Trial DeliverySeptember 12th 2025
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Merck Reports Strong Phase II Results for Ifinatamab Deruxtecan in Extensive-Stage Small Cell Lung Cancer
2
Phase IV Trial Shows Daybue Demonstrates Real-World Behavioral Improvements in Rett Syndrome
3
ACT Brief Weekly Recap: How AI, eClinical Innovation, and Policy Shifts Are Reshaping Clinical Research
4
Capvaxive Demonstrates Robust Immune Responses in Children, Adolescents at Increased Risk of Pneumococcal Disease
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
